[Surgery and combined chemotherapy of ovarian cancer].
Takahiro Kasamatsu, Ryosuke Tsunematsu
Abstract
Takahiro Kasamatsu, Ryosuke Tsunematsu
Abstract
A) Common epithelial cancer: According to the Japanese statistics on ovarian cancer, the incidence of combined radiotherapy decreased recently from about 30% to about 5% and the combined treatment used is now mainly chemotherapy. The main drug used for combined chemotherapy is cis-DDP, especially PAC (cis-DDP, Adriamycin and Cyclophosphamide) treatment. According to our clinical experience, the survival curve of advanced cases treated with PAC in combination is better than that with former drugs. B) Endodermal sinus tumor (EST): According to our treatment results, 6 patients with EST treated in combination with radiotherapy or previous forms of chemotherapy died within 2 years. However, 4 patients with EST given combined treatment with VAC (Vincristine, Actinomycin D, Cyclophosphamide) or with PVB (cis-DDP, Vinblastine, Bleomycin) were able to survive over 2 years. The Japanese statistics show that the rate of long survival of EST patients treated in combination with VAC or with PVB is about 50%.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A) Common epithelial cancer: According to the Japanese statistics on ovarian cancer, the incidence of combined radiotherapy decreased recently from about 30% to about 5% and the combined treatment used is now mainly chemotherapy. The main drug used for combined chemotherapy is cis-DDP, especially PAC (cis-DDP, Adriamycin and Cyclophosphamide) treatment. According to our clinical experience, the survival curve of advanced cases treated with PAC in combination is better than that with former drugs. B) Endodermal sinus tumor (EST): According to our treatment results, 6 patients with EST treated in combination with radiotherapy or previous forms of chemotherapy died within 2 years. However, 4 patients with EST given combined treatment with VAC (Vincristine, Actinomycin D, Cyclophosphamide) or with PVB (cis-DDP, Vinblastine, Bleomycin) were able to survive over 2 years. The Japanese statistics show that the rate of long survival of EST patients treated in combination with VAC or with PVB is about 50%.
Key concepts: Vinblastine, Vincristine, Bleomycin, Cyclophosphamide, Chemotherapy, Medicine, Radiation therapy, Combination chemotherapy